l carnitine dosage and timing Oral Bioavailability L Carnitine Supplements for Energy

Pierce et al., 1989

Addressing the inherent heterogeneity among HPH patients, arising from diverse etiologies, varying disease severities, and distinct comorbidities, requires future research to actively pursue patient stratification strategies leveraging biomarkers of inflammation, oxidative stress, vasoactive factors, and advanced imaging phenotypes to identify specific subgroups most likely to derive benefit from particular TCM therapies

dihydrolipoyl dehydrogenase (E 3

In the sustained activation phase, HSCs exhibit cell behavior alternations, such as excessive proliferation, fibre production, and matrix disintegration (Aydn and Akal, 2018